Gene Key advances GKL-006 HCC trial toward November safety readout
The Phase 1b study has closed enrollment at six patients and is tracking to a primary completion date that will report adverse-event and tolerability data first.
Executive Summary
- Beijing Gene Key Life Technology has completed enrollment in a Phase 1b safety study of its injectable candidate GKL-006 in patients with unresectable hepatocellular carcinoma, with the trial now active but not recruiting.
- The registered primary endpoint is adverse-event incidence and tolerability, not tumor response, positioning this as a dose and safety characterization step rather than an efficacy readout.
- The sponsor has already registered a larger Phase 2 trial pairing GKL-006 with transarterial chemoembolization, signaling that this safety readout is meant to clear the way for that combination study.
- Hepatocellular carcinoma already has approved systemic options and several later-stage competing programs, so an early safety trial of this size carries limited standalone weight but sets up the sponsor's next, larger bet.
The trial
The study, registered as NCT07713290, is a Phase 1b, single-arm, open-label trial (no control group) of GKL-006 injection in patients with CNLC stage II to IIIa unresectable hepatocellular carcinoma. It enrolled 6 patients against a target of 6, reaching full enrollment, and started dosing on April 3, 2025. The trial is conducted across sites in China and has moved to active, not recruiting status, the routine status update that follows enrollment closing at target. NCT07713290A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular CarcinomaNCT07713290
The endpoint
The registered primary endpoint is the incidence and severity of treatment-related adverse events and safety and tolerability risk, graded by NCI CTCAE v5.0 criteria (a standard toxicity grading scale), assessed from the start of treatment through 14 days after the fourth dose. Secondary endpoints track disease control rate, objective response rate, duration of response, progression-free survival, one-year overall survival, and pharmacokinetic and pharmacodynamic measures including NK-cell and T-cell biomarkers, all measured by mRECIST criteria for liver tumor response. No results have posted on the trial's registry record. NCT07713290A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular CarcinomaNCT07713290
The sponsor's plan
Beijing Gene Key Life Technology has a second, larger trial already registered for GKL-006: a 48-patient Phase 2 study combining the drug with transarterial chemoembolization (TACE), a standard liver-directed procedure, in the same unresectable hepatocellular carcinoma population. That trial is not yet recruiting and carries its own primary completion date of October 31, 2026. The sequencing indicates the Phase 1b safety data are intended to support moving into the combination study rather than stand as a terminal readout on their own. NCT07713290A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular CarcinomaNCT07713290
The competitive field
Hepatocellular carcinoma already has multiple approved systemic therapies, including sorafenib, cabozantinib, and the durvalumab-tremelimumab combination, each approved specifically in unresectable or advanced HCC. The active trial landscape for the indication includes later-stage competing programs such as Suzhou Suncadia's SHR-8068 in Phase 3 and AbbVie's livmoniplimab in Phase 2, neither of which shares GKL-006's mechanism or modality on the record available. GKL-006's molecular target and mechanism class are not resolved in available records, so no claim of novelty or first-in-class status applies here; the comparison rests on trial stage and indication rather than mechanism. Against that backdrop, a six-patient open-label safety cohort establishes tolerability data points but does not itself alter the competitive standing of later-stage, larger programs already underway in the same disease.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.